677 related articles for article (PubMed ID: 24002425)
21. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
Kaye KS; Pogue JM
Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
23. Colonization with antibiotic-resistant Gram-negative bacilli in the neonatal intensive care unit.
Toltzis P
Minerva Pediatr; 2003 Oct; 55(5):385-93. PubMed ID: 14608262
[TBL] [Abstract][Full Text] [Related]
24. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.
Moriyama B; Henning SA; Neuhauser MM; Danner RL; Walsh TJ
Ann Pharmacother; 2009 Jul; 43(7):1324-37. PubMed ID: 19584386
[TBL] [Abstract][Full Text] [Related]
25. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia.
Gruson D; Hilbert G; Vargas F; Valentino R; Bui N; Pereyre S; Bebear C; Bebear CM; Gbikpi-Benissan G
Crit Care Med; 2003 Jul; 31(7):1908-14. PubMed ID: 12847382
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
[TBL] [Abstract][Full Text] [Related]
27. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ
Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981
[TBL] [Abstract][Full Text] [Related]
28. Treatment of multidrug-resistant Gram-negative infections in children.
Hsu AJ; Tamma PD
Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
[TBL] [Abstract][Full Text] [Related]
29. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
Reffert JL; Smith WJ
Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.
Furtado GH; Cardinal L; Macedo RS; Silva JO; Medeiros EA; Kuti JL; Nicolau DP
Rev Soc Bras Med Trop; 2015; 48(5):539-45. PubMed ID: 26516962
[TBL] [Abstract][Full Text] [Related]
31. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
32. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia.
Ferrara AM
Int J Antimicrob Agents; 2006 Mar; 27(3):183-95. PubMed ID: 16472990
[TBL] [Abstract][Full Text] [Related]
33. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
[TBL] [Abstract][Full Text] [Related]
35. Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing health care-associated infections: A multicenter comparison.
Lai CC; Shi ZY; Chen YH; Wang FD
J Microbiol Immunol Infect; 2016 Feb; 49(1):74-82. PubMed ID: 26586483
[TBL] [Abstract][Full Text] [Related]
36. Resistant gram-negative infections.
Fraimow H; Nahra R
Crit Care Clin; 2013 Oct; 29(4):895-921. PubMed ID: 24094384
[TBL] [Abstract][Full Text] [Related]
37. [Extended spectrum beta-lactamse (ESBL)-induced antibiotics resistance in gram-negative agents: what should be watched in intensive care medicine?].
Kola A; Gastmeier P
Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Sep; 38(9):573-6. PubMed ID: 12975735
[TBL] [Abstract][Full Text] [Related]
38. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
[TBL] [Abstract][Full Text] [Related]
39. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
[TBL] [Abstract][Full Text] [Related]
40. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
Hawkey P; Finch R
Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
